A Harvard and Massachusetts General Hospital study found that an artificial intelligence model incorporating multiple methods of machine learning accurately detects thyroid cancer and predicts pathological and genomic outcomes through analysis of routine ultrasound images.
A phase II trial led by University of Michigan researchers found that PET scans obtained before and midway through treatment for p16-positive oropharynx cancer (OPC) can help determine whether a patient can receive a lower dose of radiation therapy in the second half of their treatment course without compromising cancer control.
A multi-institutional study demonstrated that a blood test to detect circulating tumor DNA can accurately predict recurrence of HPV-driven oropharyngeal cancer following treatment. Results also indicated that the biomarker test may detect recurrent disease earlier than imaging or other standard methods of post-treatment surveillance.
Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and Memorial Sloan Kettering Cancer Center showed that a small group of chronic lymphocytic leukemia patients experienced treatment-resistant mutations in a clinical trial for Loxo-305 (pirtobrutinib).
The American Cancer Society’s National Consortium for Cancer Screening and Care announced nine consensus recommendations to accelerate recovery from the pandemic and improve access to cancer screening and care.Â
A team from the SWOG Cancer Research Network that analyzed data on more than 20,000 patients from more than 200 clinical trials reports found that compared to men, women have a higher risk of severe adverse events from targeted therapy and immunotherapy. Past research has also shown that women tend to have more adverse events from chemotherapy.
A study led by researchers at Yale Cancer Center and the University of Maryland Comprehensive Cancer Center showed that ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to ixabepilone (IXA) alone. The data show it also may significantly extend both progression free survival and overall survival.Â
A study led by Yale Cancer Center researchers showed enfortumab vedotin is effective in patients with muscle-invasive bladder cancer not eligible for cisplatin chemotherapy.Â
Interim results from the single center, randomized, phase III MIRAGE trial, a UCLA-led study comparing MRIdian MRI-guided vs. CT-guided stereotactic body radiotherapy (SBRT) for localized prostate cancer, signaled superiority of MRIdian MRI-guided SBRT with a significant reduction in acute grade ≥2 GU toxicity in men receiving MRI-guided SBRT over those receiving CT-guided SBRT.
Breast cancer has surpassed lung cancer as the leading cause of cancer death among Black women as of 2019, according to a report from the American Cancer Society.Â
